The reiteration of a Buy rating and maintenance of a $30 price target by a reputable analyst firm like HC Wainwright & Co. could positively influence investor sentiment towards BioCryst Pharma. This endorsement reaffirms the firm's confidence in the company's future performance and potential for stock price appreciation, likely leading to a positive short-term impact on the stock.